Collaborations

Portola recognizes the importance of collaborations to maximize the potential of our lead product candidates.

Andexanet alfa

Portola entered into Phase 2 and Phase 3 clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors. These partnerships are non-exclusive clinical collaborations, in which the partners are providing cash payments, development and regulatory input. Portola retains all commercial rights to andexanet alfa.

In October 2012, Portola entered into a three-way agreement with Bristol-Myers Squibb and Pfizer to include a cohort dosed with their Factor Xa inhibitor, Eliquis® (apixaban), as part of Portola’s Phase 2 proof-of-concept study of andexanet alfa. In January 2014, the companies entered into a second agreement that extended the clinical collaboration through a Phase 3 study known as ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Apixaban), and potential U.S. and EU regulatory approval of andexanet alfa. Portola is responsible for conducting the clinical studies and retains full, worldwide commercialization rights to andexanet alfa.

In February 2013, Portola entered into a three-way agreement with Bayer and Janssen to include a cohort dosed with their Factor Xa inhibitor , XARELTO®(rivaroxaban), as part of Portola’s Phase 2 proof-of-concept study of andexanet alfa. In February 2014, the companies entered into a second agreement that extended the clinical collaboration through a Phase 3 study, known as ANNEXA™-R (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors – Rivaroxaban), and potential U.S. and EU regulatory approval of andexanet alfa. Portola is responsible for conducting the clinical studies and retains full, worldwide commercialization rights to andexanet alfa.

In June 2013, Portola Pharmaceuticals entered into a clinical collaboration agreement with Daiichi Sankyo Company, Limited to conduct a Phase 2 study evaluating the safety and effectiveness of andexanet alfa in reversing the anticoagulant effects of Daiichi Sankyo’s Factor Xa inhibitor Savaysa® (edoxaban).

In July 2014, we entered into a second collaboration agreement with Daiichi Sankyo to evaluate andexanet alfa as a reversal agent for the oral fXa inhibitor edoxaban through Phase 3 studies.   In January 2016, we entered into collaboration agreements with Bayer to obtain the right to pursue final regulatory approval and commercialize Andexanet alfa as a reversal agent in Japan.

In January 2016, Portola licensed lead development and commercial rights to its andexanet alfa in Japan to Bristol-Myers Squibb Company and Pfizer Inc., to be developed as an antidote for apixaban and other Factor Xa inhibitors. Separately, Portola has entered into a clinical collaboration agreement with Bayer HealthCare to include its Factor Xa inhibitor rivaroxaban in this clinical development program in Japan.


Syk Selective Inhibitors

In May 2015, Portola Pharmaceuticals announced a collaboration with Ora, Inc. for the development of Portola’s highly selective Syk inhibitor, PRT2761, in ophthalmic diseases.